184 related articles for article (PubMed ID: 35679831)
1. LAight® Therapy Is an Effective Treatment Option to Maintain Long-Term Remission of Hurley I and II Hidradenitis Suppurativa: Results from Period B of RELIEVE, a Multicenter Randomized, Controlled Trial.
Schultheis M; Staubach P; Grabbe S; Ruckes C; von Stebut E; Kirschner U; Matusiak Ł; Szepietowski JC; Nikolakis G
Dermatology; 2022; 238(6):1092-1103. PubMed ID: 35679831
[TBL] [Abstract][Full Text] [Related]
2. LAight® Therapy Significantly Enhances Treatment Efficacy of 16 Weeks of Topical Clindamycin Solution in Hurley I and II Hidradenitis Suppurativa: Results from Period A of RELIEVE, a Multicenter Randomized, Controlled Trial.
Schultheis M; Staubach P; Nikolakis G; Grabbe S; Ruckes C; von Stebut E; Kirschner U; Matusiak Ł; Szepietowski JC
Dermatology; 2022; 238(3):476-486. PubMed ID: 34535610
[TBL] [Abstract][Full Text] [Related]
3. Two Cases of Hidradenitis Suppurativa Treated with Adalimumab at the Department of Dermatology and Venereology, Clinical Hospital Mostar.
Lovrić I; Brkić J; Ćorluka M; Čović M; Pejić J; Zeljko Penavić J
Acta Dermatovenerol Croat; 2021 Jul; 29(2):108-110. PubMed ID: 34477078
[TBL] [Abstract][Full Text] [Related]
4. Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials.
Jemec GBE; Okun MM; Forman SB; Gulliver WPF; Prens EP; Mrowietz U; Armstrong AW; Geng Z; Gu Y; Williams DA; Teixeira HD; Kimball AB
Br J Dermatol; 2019 Nov; 181(5):967-975. PubMed ID: 30916379
[TBL] [Abstract][Full Text] [Related]
5. Clindamycin versus clindamycin plus rifampicin in hidradenitis suppurativa treatment: Clinical and ultrasound observations.
Caposiena Caro RD; Cannizzaro MV; Botti E; Di Raimondo C; Di Matteo E; Gaziano R; Bianchi L
J Am Acad Dermatol; 2019 May; 80(5):1314-1321. PubMed ID: 30502416
[TBL] [Abstract][Full Text] [Related]
6. Clindamycin-Benzoyl Peroxide Gel Compared with Clindamycin Lotion for Hidradenitis Suppurativa: A Randomized Controlled Assessor-Blinded Intra-Patient Pilot Study.
Aarts P; Reeves JL; Ardon CB; van der Zee HH; Prens EP
Dermatology; 2023; 239(4):670-674. PubMed ID: 37080176
[TBL] [Abstract][Full Text] [Related]
7. Lymecycline vs. clindamycin plus rifampicin in hidradenitis suppurativa treatment: clinical and ultrasonography evaluation.
Caposiena Caro RD; Molinelli E; Brisigotti V; Offidani A; Bianchi L
Clin Exp Dermatol; 2021 Jan; 46(1):96-102. PubMed ID: 32683727
[TBL] [Abstract][Full Text] [Related]
8. Combining Deroofing with LAight
Schultheis M; Scheuern M; Radkov I
Clin Pract; 2021 Jan; 11(1):26-31. PubMed ID: 33506816
[TBL] [Abstract][Full Text] [Related]
9. Real-world effectiveness and safety of the LAight-therapy in patients with hidradenitis suppurativa.
Strobel A; Schultheis M; Staubach P; Grabbe S; Mann C; Hennig K; Szepietowski JC; Matusiak L; Krajewski P; von Stebut E; Garcovich S; Bayer H; Heise M; Podda M; Kirschner U; Nikolakis G
J Dtsch Dermatol Ges; 2024 May; ():. PubMed ID: 38807028
[TBL] [Abstract][Full Text] [Related]
10. Improved clinical effectiveness of adalimumab when initiated with clindamycin and rifampicin in hidradenitis suppurativa.
Aarts P; van Huijstee JC; van der Zee HH; van Straalen KR; Prens EP
J Eur Acad Dermatol Venereol; 2024 May; 38(5):904-909. PubMed ID: 38112226
[TBL] [Abstract][Full Text] [Related]
11. Resorcinol 10% as a Promising Therapeutic Option for Mild Hidradenitis Suppurativa: A Prospective, Randomized, Open Study.
Katoulis A; Efthymiou O; Liakou A; Pappa G; Kanelleas A; Koumaki D; Bozi E; Sgouros D
Skin Appendage Disord; 2023 Dec; 9(6):438-443. PubMed ID: 38058541
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial.
Glatt S; Jemec GBE; Forman S; Sayed C; Schmieder G; Weisman J; Rolleri R; Seegobin S; Baeten D; Ionescu L; Zouboulis CC; Shaw S
JAMA Dermatol; 2021 Nov; 157(11):1279-1288. PubMed ID: 34406364
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of topical resorcinol 15% versus topical clindamycin 1% in the management of mild-to-moderate hidradenitis suppurativa: A retrospective study.
Molinelli E; Brisigotti V; Simonetti O; Sapigni C; D'Agostino GM; Rizzetto G; Giacchetti A; Offidani A
Dermatol Ther; 2022 Jun; 35(6):e15439. PubMed ID: 35278025
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of a combined pharmacological and surgical approach in patients affected by hidradenitis suppurativa: data from a retrospective real-world clinical study.
Malvaso D; Chiricozzi A; Fossati B; Antonelli F; Peris K
Ital J Dermatol Venerol; 2024 Apr; 159(2):190-195. PubMed ID: 38650499
[TBL] [Abstract][Full Text] [Related]
15. Certolizumab pegol in the treatment of severe hidradenitis suppurativa after adalimumab failure: A real-life experience.
Esme P; Akoglu G; Dalkıran CD; Caliskan E
Dermatol Ther; 2022 Nov; 35(11):e15782. PubMed ID: 35996992
[TBL] [Abstract][Full Text] [Related]
16. Why rifampin (rifampicin) is a key component in the antibiotic treatment of hidradenitis suppurativa: a review of rifampin's effects on bacteria, bacterial biofilms, and the human immune system.
Scheinfeld N
Dermatol Online J; 2016 Jun; 22(6):. PubMed ID: 27617596
[TBL] [Abstract][Full Text] [Related]
17. [Impact of LAight therapy on hidradenitis suppurativa care].
Zimmer S; Basien K; von Stebut E
Hautarzt; 2021 Jul; 72(7):586-594. PubMed ID: 34125251
[TBL] [Abstract][Full Text] [Related]
18. Clindamycin as unique antibiotic choice in Hidradenitis Suppurativa.
Rosi E; Pescitelli L; Ricceri F; Di Cesare A; Novelli A; Pimpinelli N; Prignano F
Dermatol Ther; 2019 Mar; 32(2):e12792. PubMed ID: 30515931
[TBL] [Abstract][Full Text] [Related]
19. [Topical and novel device-based therapies for mild hidradenitis suppurativa].
Nikolakis G; von Stebut E
Hautarzt; 2021 Aug; 72(8):676-685. PubMed ID: 34223936
[TBL] [Abstract][Full Text] [Related]
20. Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment.
Kimball AB; Jemec GB; Yang M; Kageleiry A; Signorovitch JE; Okun MM; Gu Y; Wang K; Mulani P; Sundaram M
Br J Dermatol; 2014 Dec; 171(6):1434-42. PubMed ID: 25040429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
